Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00658671 · ClinicalTrials.gov registry record · Phase 1

A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer

A Phase 1 study of Advanced Cancer, sponsored by CASI Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
67
Enrollment target
2
Study locations

NCT00658671 is a Phase 1 study of Advanced Cancer that has completed, run by CASI Pharmaceuticals. The registered enrollment target is 67 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00658671, a Phase 1 study of Advanced Cancer, has completed, sponsored by CASI Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
67 participants
Enrollment target
2
Study locations

Study Summary

A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.

Conditions Studied

Advanced Cancer

Interventions

  • DRUG ENMD-2076

Study Locations (2)

Colorado

  • University of Colorado Hospital - Aurora

Massachusetts

  • Dana Farber/Harvard Cancer Center - Boston

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2008-04
Est. Completion 2012-06
Phase Phase 1

Sponsor

CASI Pharmaceuticals

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00658671

The ClinicalTrials.gov registry entry for NCT00658671 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (73% lower). The listed sponsor is CASI Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which ENMD-2076 is the first listed.

NCT00658671 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00658671 about?

NCT00658671 is a clinical study titled "A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer". A dose-escalation trial designed to assess the safety and tolerability of treatment with ENMD-2076 administered orally over a range of doses in patients with advanced cancer that is refractory to current treatment or for which no curative therapy exists.

What is the current status of trial NCT00658671?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2008-04. Estimated completion is 2012-06.

What conditions does trial NCT00658671 study?

This clinical trial studies the following conditions: Advanced Cancer.

What interventions are being tested in trial NCT00658671?

The interventions under investigation include: ENMD-2076 (DRUG).

Who is sponsoring clinical trial NCT00658671?

This trial is sponsored by CASI Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00658671 being conducted?

This trial has 2 study locations across Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.